MX2010005225A - Derivados de fenilpirazol. - Google Patents

Derivados de fenilpirazol.

Info

Publication number
MX2010005225A
MX2010005225A MX2010005225A MX2010005225A MX2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A MX 2010005225 A MX2010005225 A MX 2010005225A
Authority
MX
Mexico
Prior art keywords
alkyl
formula
halogen
heterocyclic ring
saturated
Prior art date
Application number
MX2010005225A
Other languages
English (en)
Spanish (es)
Inventor
Shigeyuki Chaki
Dai Nozawa
Tomoko Tamita
Toshio Nakamura
Makoto Tatsuzuki
Seiji Masuda
Hiroshi Ohta
Shuhei Kashiwa
Aya Fujino
Toshiharu Shimazaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2010005225A publication Critical patent/MX2010005225A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2010005225A 2007-11-13 2008-11-13 Derivados de fenilpirazol. MX2010005225A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2008153736 2008-06-12
PCT/JP2008/070712 WO2009063953A1 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体

Publications (1)

Publication Number Publication Date
MX2010005225A true MX2010005225A (es) 2010-05-27

Family

ID=40638800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005225A MX2010005225A (es) 2007-11-13 2008-11-13 Derivados de fenilpirazol.

Country Status (24)

Country Link
US (3) US7888354B2 (enExample)
EP (1) EP2221298B1 (enExample)
JP (2) JP4543344B2 (enExample)
KR (1) KR101571176B1 (enExample)
CN (1) CN101855211B (enExample)
AU (1) AU2008321823B2 (enExample)
BR (1) BRPI0820432B8 (enExample)
CA (1) CA2705502C (enExample)
CY (1) CY1114877T1 (enExample)
DK (1) DK2221298T3 (enExample)
ES (1) ES2436146T3 (enExample)
HR (1) HRP20131060T1 (enExample)
IL (2) IL205509A (enExample)
MX (1) MX2010005225A (enExample)
MY (1) MY173546A (enExample)
NZ (1) NZ585661A (enExample)
PH (1) PH12012501917A1 (enExample)
PL (1) PL2221298T3 (enExample)
PT (1) PT2221298E (enExample)
RS (1) RS53125B (enExample)
RU (1) RU2480456C2 (enExample)
SI (1) SI2221298T1 (enExample)
WO (1) WO2009063953A1 (enExample)
ZA (1) ZA201003111B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072724A1 (ja) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
AU2008321823B2 (en) * 2007-11-13 2013-03-07 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
JP5740838B2 (ja) * 2009-05-12 2015-07-01 大正製薬株式会社 フェニルピラゾール誘導体
US9284324B2 (en) * 2011-12-08 2016-03-15 Taisho Pharmaceutical Co., Ltd Phenylpyrrole derivative
TW201343636A (zh) * 2011-12-27 2013-11-01 大正製藥股份有限公司 苯基三唑衍生物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2014089495A1 (en) * 2012-12-07 2014-06-12 Chemocentryx, Inc. Diazole lactams
JP6263553B2 (ja) 2013-01-17 2018-01-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cns疾患の処置のためのオキシトシン受容体アゴニスト
PL3439653T3 (pl) 2016-04-07 2021-07-05 Chemocentryx, Inc. Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
CA2419036A1 (en) 2000-08-08 2002-02-14 Ortho-Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
JP4612990B2 (ja) * 2001-03-16 2011-01-12 アボット・ラボラトリーズ ヒスタミン−3受容体リガンドとしての新規アミンおよびそれらの治療的適用
JP4735261B2 (ja) 2003-06-27 2011-07-27 Msd株式会社 ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体
CA2561791A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
BRPI0514553A (pt) 2004-08-23 2008-06-17 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
RU2391338C2 (ru) 2004-10-19 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные хинолина
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
EP1820797A4 (en) * 2004-12-01 2009-10-28 Banyu Pharma Co Ltd SUBSTITUTED PYRIDONE DERIVATIVE
AU2005313550A1 (en) 2004-12-07 2006-06-15 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
US7790720B2 (en) * 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
EP1868991B1 (en) 2005-04-01 2014-07-30 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
DE102005033448A1 (de) * 2005-07-18 2007-01-25 Josef Gail Druckgas-Zylinderläufermotor
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2641441A1 (en) * 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders
WO2008072724A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
EP2134673A1 (en) * 2007-04-12 2009-12-23 DSM Fine Chemicals Austria Nfg GmbH & Co KG Improved process for preparing o-chloromethylphenylglyoxylic esters, improved process for preparing (e)-2-(2-chloromethylphenyl)-2-alkoximinoacetic esters, and novel intermediates for their preparation
AU2008321823B2 (en) * 2007-11-13 2013-03-07 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives

Also Published As

Publication number Publication date
HK1145834A1 (en) 2011-05-06
US7888354B2 (en) 2011-02-15
BRPI0820432B8 (pt) 2021-05-25
EP2221298B1 (en) 2013-11-06
JPWO2009063953A1 (ja) 2011-03-31
KR20100083795A (ko) 2010-07-22
BRPI0820432B1 (pt) 2020-01-14
US8193176B2 (en) 2012-06-05
EP2221298A4 (en) 2011-09-21
US8183387B2 (en) 2012-05-22
RS53125B (sr) 2014-06-30
AU2008321823A1 (en) 2009-05-22
BRPI0820432A2 (pt) 2015-05-26
AU2008321823B2 (en) 2013-03-07
PL2221298T3 (pl) 2014-05-30
US20110065668A1 (en) 2011-03-17
IL205509A (en) 2015-09-24
CA2705502C (en) 2016-01-26
MY173546A (en) 2020-02-04
PT2221298E (pt) 2013-12-03
RU2480456C2 (ru) 2013-04-27
DK2221298T3 (da) 2013-11-18
US20110065667A1 (en) 2011-03-17
JP5375639B2 (ja) 2013-12-25
CN101855211A (zh) 2010-10-06
CA2705502A1 (en) 2009-05-22
PH12012501917A1 (en) 2014-10-17
JP4543344B2 (ja) 2010-09-15
RU2010123924A (ru) 2011-12-20
SI2221298T1 (sl) 2013-12-31
IL205509A0 (en) 2010-12-30
KR101571176B1 (ko) 2015-11-23
ES2436146T3 (es) 2013-12-27
JP2010143943A (ja) 2010-07-01
US20100267687A1 (en) 2010-10-21
CY1114877T1 (el) 2016-12-14
IL236083A0 (en) 2015-01-29
CN101855211B (zh) 2013-06-12
ZA201003111B (en) 2011-08-31
IL236083A (en) 2016-12-29
NZ585661A (en) 2012-04-27
WO2009063953A1 (ja) 2009-05-22
EP2221298A1 (en) 2010-08-25
HRP20131060T1 (hr) 2013-12-20

Similar Documents

Publication Publication Date Title
MX2010005225A (es) Derivados de fenilpirazol.
BR112014003496A2 (pt) derivado heterocíclico e fármaco
AR067051A1 (es) Indazoles sustituidos, su preparacion y su utilizacion terapeutica
PA8534801A1 (es) Derivados de piperazina
AR036604A1 (es) Derivados de 4-pirimidona 3-sustituida
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
NO20076134L (no) Benzamidderivater og anvendelser derav
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
MX2011008336A (es) Derivados de dihidroquinolinona.
NO20083710L (no) Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser
AR082667A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
SE0104341D0 (sv) New use
UY27204A1 (es) Derivados de pieracina
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
MX2010001352A (es) Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares.
AR062295A1 (es) Compuesto de 1h-quinolin-4-ona, procedimientos para su preparacion y composicion farmaceutica
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
MX2016013412A (es) Derivados de morfolina-piridina.

Legal Events

Date Code Title Description
FG Grant or registration